Physician profile
Ramesh Amara
NPI 1104892959
$10,768.15
in general payments reported to CMS, 2019-2025
48 companies · $816 in 2025
The $816 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,510 · 2020: $1,667 · 2021: $1,898 · 2022: $1,769 · 2023: $1,799 · 2024: $1,308 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,923.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,272.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $876.45 | 2019-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $777.64 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $729.55 | 2019-2025 | Spravato, Xarelto |
| Pfizer INC. | $712.19 | 2019-2024 | |
| Lilly USA, LLC | $683.19 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $656.50 | 2019-2025 | Jardiance, Ofev |
| Merck Sharp & Dohme LLC | $594.26 | 2019-2025 | Belsomra, Steglatro, Steglujan |
| Abbvie INC. | $594.10 | 2019-2025 | Ubrelvy |
| Amgen INC. | $532.54 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $451.47 | 2019-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $380.05 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $252.94 | 2020-2021 | |
| Exact Sciences Corporation | $248.07 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $241.23 | 2021-2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Amara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.